{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T12:08:29Z","timestamp":1783339709159,"version":"3.54.6"},"reference-count":22,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T00:00:00Z","timestamp":1537488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Millennium Pharmaceuticals, Inc."}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>First\u2010line treatments for classical Hodgkin lymphoma (<jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content>) include <jats:styled-content style=\"fixed-case\">ABVD<\/jats:styled-content> (adriamycin, bleomycin, vinblastine, dacarbazine) and <jats:styled-content style=\"fixed-case\">BEACOPP<\/jats:styled-content><jats:sub>escalated<\/jats:sub> (escalated dose bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone). To further improve overall outcomes, positron emission tomography\u2010driven strategies and <jats:styled-content style=\"fixed-case\">ABVD<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">BEACOPP<\/jats:styled-content> variants incorporating the antibody\u2010drug conjugate brentuximab vedotin (<jats:styled-content style=\"fixed-case\">BV<\/jats:styled-content>) or anti\u2010<jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>1 antibodies are under investigation in advanced\u2010stage patients. The present study aimed to elicit preferences for attributes associated with <jats:styled-content style=\"fixed-case\">ABVD<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> BEACOPP<\/jats:styled-content><jats:sub>escalated<\/jats:sub> and <jats:styled-content style=\"fixed-case\">BV<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">AVD<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">BV<\/jats:styled-content>, adriamycin, vinblastine and dacarbazine) among patients and physicians. Cross\u2010sectional online discrete choice experiments were administered to <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content> patients (<jats:italic>n<\/jats:italic>\u00a0=\u00a0381) and haematologists\/oncologists (<jats:italic>n\u00a0<\/jats:italic>=\u00a0357) in France, Germany and the United Kingdom. Included attributes were progression\u2010free survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>), overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>), and the risk of neuropathy, lung damage, infertility and hospitalisation due to adverse events. Whereas 5\u2010year <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> were the most important treatment attributes to patients, the relative importance of each attribute and preference weights for each level varied among physicians according to the description of the hypothetical patient for whom treatment was recommended. <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> most strongly influenced physicians\u2019 recommendations when considering young female patients who did not want children or young male patients. Infertility was more important to physicians\u2019 treatment decision than <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> when considering young women with unknown fertility preferences, whereas hospitalisations due to adverse events played the largest role in treatment decisions for older patients.<\/jats:p>","DOI":"10.1111\/bjh.15566","type":"journal-article","created":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T02:12:20Z","timestamp":1537582340000},"page":"202-214","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Patient and physician preferences for first\u2010line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom"],"prefix":"10.1111","volume":"184","author":[{"given":"Paul J.","family":"Br\u00f6ckelmann","sequence":"first","affiliation":[{"name":"Department I of Internal Medicine University Hospital of Cologne Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"McMullen","sequence":"additional","affiliation":[{"name":"Epidemiology ICON plc Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Ben","family":"Wilson","sequence":"additional","affiliation":[{"name":"Epidemiology ICON plc Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3315-4674","authenticated-orcid":false,"given":"Kerstin","family":"Mueller","sequence":"additional","affiliation":[{"name":"Epidemiology ICON plc Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Goring","sequence":"additional","affiliation":[{"name":"Epidemiology ICON plc Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aspasia","family":"Stamatoullas","sequence":"additional","affiliation":[{"name":"Centre Henri Becquerel Rouen Cedex France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Zagadailov","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Gautam","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Huebner","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul","family":"Dalal","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Illidge","sequence":"additional","affiliation":[{"name":"Institute of Cancer Sciences University of Manchester Christie Hospital Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,9,21]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.tps8613"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.3721"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30215-7"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32134-7"},{"issue":"5","key":"e_1_2_7_6_1","first-page":"61","article-title":"Patient preferences \u2013 survey of Hodgkin Lymphoma survivors on treatment\u2010associated burden and side effects","volume":"101","author":"Buerkle C.","year":"2016","journal-title":"Haematologica"},{"key":"e_1_2_7_7_1","unstructured":"Cancer Research UK. (2017).Hodgkin lymphoma incidence statistics[Online]. Available from:http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/hodgkin-lymphoma\/incidence#heading-One."},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.5648"},{"key":"e_1_2_7_9_1","first-page":"6","article-title":"Brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine (A+AVD) As frontline therapy demonstrates superior modified progression\u2010free survival versus ABVD in patients with previously untreated stage III or IV Hodgkin lymphoma (HL): the phase 3 Echelon\u20101 study","volume":"130","author":"Connors J.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30696-4"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy080"},{"key":"e_1_2_7_12_1","unstructured":"EMA. (2013).The patient's voice in the evaluation of medicines[Online]. European Medicines Agency. Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2013\/10\/WC500153276.pdf."},{"key":"e_1_2_7_13_1","unstructured":"FDA. (2017).Patient preference initiative[Online]. Food and Drug Administration. Available from:https:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDRH\/CDRHPatientEngagement\/ucm462830.htm."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0910"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa012528"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510093"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30093-6"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu189"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505949"},{"key":"e_1_2_7_20_1","unstructured":"SEER. (2016).SEER cancer statistics factsheets: Hodgkin lymphoma[Online].Bethesda MD:National Cancer Institute. Available from:https:\/\/seer.cancer.gov\/statfacts\/html\/hodg.html[Accessed 27 April 2014]."},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.225"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70341-3"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70501-1"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15566","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15566","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.15566","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:58:50Z","timestamp":1694393930000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,21]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1111\/bjh.15566"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15566","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,21]]},"assertion":[{"value":"2018-04-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}